U09 Stock Overview
Medcaw Investments Plc intends to undertake an acquisition or acquisitions in the life sciences sector focusing on companies developing medical or wellness technologies and therapies.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Medcaw Investments Plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.041 |
| 52 Week High | UK£0.11 |
| 52 Week Low | UK£0.022 |
| Beta | 0 |
| 11 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -64.16% |
Recent News & Updates
Recent updates
Shareholder Returns
| U09 | DE Capital Markets | DE Market | |
|---|---|---|---|
| 7D | 0% | 0.8% | -0.5% |
| 1Y | n/a | 23.8% | 1.6% |
Return vs Industry: Insufficient data to determine how U09 performed against the German Capital Markets industry.
Return vs Market: Insufficient data to determine how U09 performed against the German Market.
Price Volatility
| U09 volatility | |
|---|---|
| U09 Average Weekly Movement | n/a |
| Capital Markets Industry Average Movement | 4.8% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.5% |
| 10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: U09 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine U09's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | 3 | n/a | medcaw-invest.com |
Medcaw Investments Plc intends to undertake an acquisition or acquisitions in the life sciences sector focusing on companies developing medical or wellness technologies and therapies. The company was incorporated in 2020 and is based in London, the United Kingdom.
Medcaw Investments Plc Fundamentals Summary
| U09 fundamental statistics | |
|---|---|
| Market cap | €1.02m |
| Earnings (TTM) | -€223.69k |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-4.6x
P/E RatioIs U09 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| U09 income statement (TTM) | |
|---|---|
| Revenue | UK£0 |
| Cost of Revenue | UK£0 |
| Gross Profit | UK£0 |
| Other Expenses | UK£194.01k |
| Earnings | -UK£194.01k |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0088 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did U09 perform over the long term?
See historical performance and comparison